Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.502EUR
−6.79 MEUR
9.18 MEUR
1.53 M
About MARINOMED BIOTECH AG
Sector
CEO
Andreas Grassauer
Headquarters
Korneuburg
Website
Employees (FY)
52
Founded
2006
ISIN
ATMARINOMED6
FIGI
BBG00N6LCYN3
Marinomed Biotech AG is a biopharmaceutical company, which engages in the development of therapies based on patent protected technology platforms. It operates through the following segments: Immunology, Virology, and Other. The company was founded by Andreas Grassauer and Eva Prieschl-Grassauer in 2006 and is headquartered in Korneuburg, Austria.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange Marinomed Biotech AG stocks are traded under the ticker 93Z.
We've gathered analysts' opinions on Marinomed Biotech AG future price: according to them, 93Z price has a max estimate of 16.40 EUR and a min estimate of 16.40 EUR. Watch 93Z chart and read a more detailed Marinomed Biotech AG stock forecast: see what analysts think of Marinomed Biotech AG and suggest that you do with its stocks.
Yes, you can track Marinomed Biotech AG financials in yearly and quarterly reports right on TradingView.
Marinomed Biotech AG is going to release the next earnings report on Aug 20, 2024. Keep track of upcoming events with our Earnings Calendar.
93Z net income for the last quarter is −2.13 M EUR, while the quarter before that showed −1.19 M EUR of net income which accounts for −78.84% change. Track more Marinomed Biotech AG financial stats to get the full picture.
No, 93Z doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 12, 2024, the company has 52.00 employees. See our rating of the largest employees — is Marinomed Biotech AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Marinomed Biotech AG EBITDA is −4.94 M EUR, and current EBITDA margin is −63.40%. See more stats in Marinomed Biotech AG financial statements.
Like other stocks, 93Z shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Marinomed Biotech AG stock right from TradingView charts — choose your broker and connect to your account.